LOX and pancreatic neoplasm: These findings were corroborated by in vivo experiments wherein pancreatic tumor-bearing mice treated with both gemcitabine and LOX neutralizing antibodies (αLOX) experienced significantly improved survival than animals treated with gemcitabine or αLOX alone [151].